Investigating and Resolving Cardiotoxicity Induced by COVID‐19 Treatments using Human Pluripotent Stem Cell‐Derived Cardiomyocytes and Engineered Heart Tissues-Reference-Cited by-同舟云学术

Investigating and Resolving Cardiotoxicity Induced by COVID‐19 Treatments using Human Pluripotent Stem Cell‐Derived Cardiomyocytes and Engineered Heart Tissues

Published:2022-09-02 Issue:30 Volume:9 Page:2203388
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Advanced Science

Author:

Xu He¹²,Liu Ge³,Gong Jixing⁴,Zhang Ying³⁵,Gu Shanshan³,Wan Zhongjun⁴,Yang Pengcheng⁴,Nie Yage³,Wang Yinghan³,Huang Zhan‐peng¹²,Luo Guanzheng⁵,Chen Zhongyan³,Zhang Donghui⁴,Cao Nan³^ORCID

Affiliation:

1. Center of Translational Medicine The First Affiliated Hospital Zhongshan School of Medicine Sun Yat‐Sen University Guangdong 510080 China

2. NHC Key Laboratory of Assisted Circulation (Sun Yat‐Sen University) Guangzhou 510080 China

3. The Seventh Affiliated Hospital Zhongshan School of Medicine Sun Yat‐Sen University Guangdong 510080 China

4. National & Local Joint Engineering Research Center of High‐throughput Drug Screening Technology State Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine Hubei University Wuhan 430062 China

5. MOE Key Laboratory of Gene Function and Regulation State Key Laboratory of Biocontrol School of Life Sciences Sun Yat‐Sen University Guangdong 510275 China

Funder

National Natural Science Foundation of China

Science Fund for Distinguished Young Scholars of Hubei Province

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202203388

Reference53 articles.

1. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

2. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports

3. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

4. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

5. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trials in-a-dish for cardiovascular medicine;European Heart Journal;2024-09-13

2. Sphingolipid metabolism controls mammalian heart regeneration;Cell Metabolism;2024-04

3. Cardiac tissue model of immune-induced dysfunction reveals the role of free mitochondrial DNA and the therapeutic effects of exosomes;Science Advances;2024-03-29

4. Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes;Cell Stem Cell;2024-03

5. IL‐37 Modulates Myocardial Calcium Handling via the p‐STAT3/SERCA2a Axis in HF‐Related Engineered Human Heart Tissue;Advanced Healthcare Materials;2024-02-19